{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-022992","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.810664+00:00","generated_at":"2026-06-23T23:41:54.347376+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Interpace Q2 revenue $9.4M (-16% YoY), net loss $3.9M on ThyGeNEXT price cut","bullets":["Q2 net revenue $9.4M, down 16% YoY; net loss $3.9M vs $3.4M prior year.","Adjusted EBITDA $(2.9)M vs $(0.3)M; gross margin 37% vs 48% due to 70% retroactive ThyGeNEXT price cut.","Cash balance fell to $1.9M at June 30 from $3.8M year ago; DSO improved 15% to 59 days.","Launched Point2Glucose test; YTD net loss improved $1.5M to $(6.1)M; new thyroid data published."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-022992","json":"https://secwatch.observer/filing/0001493152-22-022992.json","markdown":"https://secwatch.observer/filing/0001493152-22-022992.md","text":"https://secwatch.observer/filing/0001493152-22-022992.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222022992/0001493152-22-022992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222022992/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:41:54.347376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}